Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Ionis partner Roche reported Phase 3 IMAgINATION data showing sefaxersen achieved a statistically significant 43.1% reduction in proteinuria versus placebo at 37 weeks in adults with IgA nephropathy (P<0.0001). Sefaxersen, a once-monthly subcutaneous antisense inhibitor of complement factor B licensed from Ionis, was well tolerated with no new safety signals, and effects were consistent across all prespecified subgroups.
Key figures
- Drug Name
- sefaxersen
- Phase Of Trial
- Phase 3
- Ci
- 95% CI: 32.5-52.0, P<0.0001
- Week endpoint
- 37
- Patients enrolled
- 459
- Study duration weeks
- 105
- Proteinuria reduction
- 43.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.